Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Update: 2025-09-16
Description
Host: Ryan Quigley
In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.
Comments
In Channel



